Joseph A Arthur1, Tonya Edwards1, Zhanni Lu1, Suresh Reddy1, David Hui1, Jimin Wu2, Diane Liu3, Janet L Williams1, Eduardo Bruera1. 1. Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer, Houston, Texas. 2. Department of Quantitative Sciences, The University of Texas MD Anderson Cancer, Houston, Texas. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer, Houston, Texas.
Abstract
BACKGROUND: Data are limited on the use and outcomes of urine drug tests (UDTs) among patients with advanced cancer. The main objective of this study was to determine the factors associated with UDT ordering and results in outpatients with advanced cancer. METHODS: A retrospective chart review was conducted of 1058 patients who attended an outpatient supportive care clinic from March 2014 to November 2015. Sixty-one patients who were receiving chronic opioid therapy and underwent UDTs were identified. A control group of 120 patients who did not undergo UDTs was selected for comparison. RESULTS: Sixty-one of 1058 patients (6%) underwent UDTs, and 33 of 61 patients (54%) had abnormal results. Multivariate analysis indicated that the odds ratio for UDT ordering was 3.9 in patients who had positive Cut Down, Annoyed, Guilty, and Eye Opener (CAGE) questionnaire results (P = .002), 4.41 in patients aged < 45 years (P < .001), 5.58 in patients who had moderate-to-severe pain (Edmonton Symptom Assessment Scale pain scores ≥4; P < .001), 0.27 in patients with advanced-stage cancer, (P = .008), and 0.25 in patients who had moderate-to-severe fatigue (P = .001). Among 52 abnormal UDT results in 33 patients, the most common opioid findings were prescribed opioids absent in urine (14 of 52 tests; 27%) and unprescribed opioids in urine (13 of 52 tests; 25%). CONCLUSIONS: UDTs were used infrequently among outpatients with advanced cancer who were receiving chronic opioid therapy. Younger age, positive CAGE questionnaire results, early stage cancer or no evidence of disease status, higher pain intensity, and lower fatigue scores were significant predictors of UDT ordering. More than 50% of UDT results were abnormal. More research is necessary to better characterize aberrant opioid use in patients with advanced cancer. Cancer 2016;122:3732-9.
BACKGROUND: Data are limited on the use and outcomes of urine drug tests (UDTs) among patients with advanced cancer. The main objective of this study was to determine the factors associated with UDT ordering and results in outpatients with advanced cancer. METHODS: A retrospective chart review was conducted of 1058 patients who attended an outpatient supportive care clinic from March 2014 to November 2015. Sixty-one patients who were receiving chronic opioid therapy and underwent UDTs were identified. A control group of 120 patients who did not undergo UDTs was selected for comparison. RESULTS: Sixty-one of 1058 patients (6%) underwent UDTs, and 33 of 61 patients (54%) had abnormal results. Multivariate analysis indicated that the odds ratio for UDT ordering was 3.9 in patients who had positive Cut Down, Annoyed, Guilty, and Eye Opener (CAGE) questionnaire results (P = .002), 4.41 in patients aged < 45 years (P < .001), 5.58 in patients who had moderate-to-severe pain (Edmonton Symptom Assessment Scale pain scores ≥4; P < .001), 0.27 in patients with advanced-stage cancer, (P = .008), and 0.25 in patients who had moderate-to-severe fatigue (P = .001). Among 52 abnormal UDT results in 33 patients, the most common opioid findings were prescribed opioids absent in urine (14 of 52 tests; 27%) and unprescribed opioids in urine (13 of 52 tests; 25%). CONCLUSIONS: UDTs were used infrequently among outpatients with advanced cancer who were receiving chronic opioid therapy. Younger age, positive CAGE questionnaire results, early stage cancer or no evidence of disease status, higher pain intensity, and lower fatigue scores were significant predictors of UDT ordering. More than 50% of UDT results were abnormal. More research is necessary to better characterize aberrant opioid use in patients with advanced cancer. Cancer 2016;122:3732-9.
Authors: Gilles J Lavigne; Alberto Herrero Babiloni; Pierre Mayer; Raoul Daoust; Marc O Martel Journal: J Clin Sleep Med Date: 2020-02-13 Impact factor: 4.062
Authors: Joseph Arthur; Kimberson Tanco; Ali Haider; Courtney Maligi; Minjeong Park; Diane Liu; Eduardo Bruera Journal: Support Care Cancer Date: 2017-04-06 Impact factor: 3.603
Authors: Nalini Vadivelu; Alice M Kai; Gopal Kodumudi; Dan Haddad; Vijay Kodumudi; Niketh Kuruvilla; Alan David Kaye; Richard D Urman Journal: Curr Pain Headache Rep Date: 2018-03-19
Authors: Dhanalakshmi Koyyalagunta; Eduardo Bruera; Mitchell P Engle; Larry Driver; Wenli Dong; Chris Demaree; Diane M Novy Journal: Pain Med Date: 2018-07-01 Impact factor: 3.750
Authors: Ali Haider; Donna S Zhukovsky; Yee Choon Meng; Joseph Baidoo; Kimberson C Tanco; Holly A Stewart; Tonya Edwards; Manju P Joy; Leela Kuriakose; Zhanni Lu; Janet L Williams; Diane D Liu; Eduardo Bruera Journal: J Oncol Pract Date: 2017-10-13 Impact factor: 3.840